跳至主要内容
临床试验/2023-505286-84-00
2023-505286-84-00招募中2 期

Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors

Institut Gustave Roussy24 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2024年3月27日最近更新:

试验速览

阶段
2 期
状态
招募中
入组人数
140
试验地点
24

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Hospital/Clinic/Other health care facility

研究点 (24)

Loading locations...

相似试验

招募中
2 期
Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomas
2024-514875-16-00Oncopole Claudius Regaud86
尚未招募
不适用
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Breast Cancer
NCT07290166Fudan University42
进行中(未招募)
不适用
A Randomized Phase II Study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxane Pretreated Advanced Breast Cancer Patients - NDWomen with histologic or cytologic diagnosis of advanced breast cancer, who have received one prior chemotherapy containing anthracyclines as neo adjuvant or palliative 1st-line treatment and one prior chemotherapy containing taxanes as neo adjuvant or palliative 1st-line treatment.MedDRA version: 8.1Level: LLTClassification code 10055113Term: Breast cancer metastatic
EUCTR2006-000441-19-ITELI LILLY160
进行中(未招募)
不适用
A randomised Phase II study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-vinorelbine, in Anthracycline and Taxane pretreated Advanced Breast cancer patients.advanced breast cancerMedDRA version: 8.0Level: LLTClassification code 10006285
EUCTR2006-000441-19-DEEli lilly and Company Limited144
已完成
2 期
Randomized phase II study comparing chemotherapy led by using the classification of primary tumor origin with empirical chemotherapy for patients with unknown primary cancer .
JPRN-UMIN000001919Ministry of Health, Labour and Welfare scientific research Nakagawa squad120